| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T36121 | ||||
| Target Name | Proto-oncogene c-Myc (MYC) | ||||
| Type of Target |
Literature-reported |
||||
| Drug Potency against Target | TWS-119 | Drug Info | IC50 = 15000 nM | [1] | |
| Action against Disease Model | Resten-MP | Drug Info | In a porcine coronary model, an advanced c-myc-eluting PC stent loaded with AVI-4126 using soak trap blocked c-myc expression and significantly inhibited myointimal hyperplasia and allowed complete reendothelialization and healing response. | [2] | |
| References | |||||
| REF 1 | Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. | ||||
| REF 2 | P-selectin antagonism with recombinant p-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther. 2001 Aug;298(2):658-64. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.